Androgen deprivation therapy may be linked to increased risk of dementiaBMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i5572 (Published 17 October 2016) Cite this as: BMJ 2016;355:i5572
- Jacqui Wise
Androgen deprivation therapy (ADT), a common treatment for prostate cancer, may be associated with an increased risk of dementia, new research in JAMA Oncology has found.1
Androgen deprivation therapy is used to reduce levels of androgens as they stimulate prostate cancer cells to grow. The approach has shown survival benefit in some patients but has also been associated with adverse health effects—for example, growing evidence supports a link between ADT and neurocognitive dysfunction.
The researchers …
Log in using your username and password
Log in through your institution
Sign up for a free trial